MedPath

Hydrochlorothiazide

Generic Name
Hydrochlorothiazide
Brand Names
Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
Drug Type
Small Molecule
Chemical Formula
C7H8ClN3O4S2
CAS Number
58-93-5
Unique Ingredient Identifier
0J48LPH2TH
Background

Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication

Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions
Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
Associated Therapies
-

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

Phase 4
Recruiting
Conditions
Primary Hypertension
Interventions
First Posted Date
2023-06-23
Last Posted Date
2024-06-10
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
96
Registration Number
NCT05917275
Locations
🇳🇱

Radboudumc, Nijmegen, Netherlands

Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

Phase 4
Not yet recruiting
Conditions
Urolithiasis
Hyperoxaluria
Interventions
First Posted Date
2022-07-05
Last Posted Date
2023-10-23
Lead Sponsor
Medical University of Vienna
Target Recruit Count
32
Registration Number
NCT05443932
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide

Active, not recruiting
Conditions
Hypertension
Interventions
Drug: Dihydropyridine calcium channel blocker
Drug: Hydrochlorothiazide
First Posted Date
2021-11-18
Last Posted Date
2023-07-18
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
163720
Registration Number
NCT05125224
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)

Phase 1
Completed
Conditions
Photosensitivity
Interventions
First Posted Date
2020-12-04
Last Posted Date
2021-11-19
Lead Sponsor
Universität des Saarlandes
Target Recruit Count
30
Registration Number
NCT04654312
Locations
🇩🇪

Saarland University Hospital, Homburg, Saarland, Germany

Sympathetic Regulation of Large Artery Stiffness in Humans With ISH

Early Phase 1
Recruiting
Conditions
Stiffness, Aortic
Hypertension, Systolic
Interventions
First Posted Date
2020-06-09
Last Posted Date
2024-04-19
Lead Sponsor
University of Iowa
Target Recruit Count
78
Registration Number
NCT04423627
Locations
🇺🇸

Amy Stroud, Iowa City, Iowa, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

Hydrochlorothiazide and Risk of Skin Cancer

Completed
Conditions
Melanoma
Hypertension
Non-melanoma Skin Cancer
Interventions
Drug: Hydrochlorothiazide
Drug: Angiotensin-converting enzyme (ACE) inhibitors
First Posted Date
2020-04-06
Last Posted Date
2023-06-29
Lead Sponsor
Canadian Network for Observational Drug Effect Studies, CNODES
Target Recruit Count
2953748
Registration Number
NCT04334824
Locations
🇨🇦

Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada

Generation of Biological Samples Positive to Hydrochlorothiazide for Anti-doping Control

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2019-12-13
Last Posted Date
2019-12-13
Lead Sponsor
Parc de Salut Mar
Target Recruit Count
3
Registration Number
NCT04197622
Locations
🇪🇸

IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

Comparison of the Impact of Diet vs Thiazide in BMD in Children With Idiopathic Hypercalciuria

Not Applicable
Conditions
Hypercalciuria; Idiopathic
Nephrolithiasis
Interventions
Other: Diet for calciuria prevention
Drug: Hydrochlorothiazide
First Posted Date
2019-05-15
Last Posted Date
2019-05-15
Lead Sponsor
Hospital Infantil de Mexico Federico Gomez
Target Recruit Count
90
Registration Number
NCT03951558
Locations
🇲🇽

Children's Hospital of Mexico, Federico Gómez, México, México City, Mexico

Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.

Phase 4
Completed
Conditions
Hypertension
Hyperuricemia
Menopause
Interventions
First Posted Date
2019-04-19
Last Posted Date
2019-04-22
Lead Sponsor
Anna Posadzy-Małaczyńska
Target Recruit Count
180
Registration Number
NCT03921736

Protocol of Diuretics Use in Congestive Therapy in Heart Failure

Phase 4
Conditions
Heart Failure
Chronic Heart Failure
Acute Heart Failure
Interventions
First Posted Date
2019-03-27
Last Posted Date
2021-04-15
Lead Sponsor
University Hospital, Clermont-Ferrand
Target Recruit Count
300
Registration Number
NCT03892148
Locations
🇫🇷

Ch Annecy, Annecy, France

🇫🇷

CH PUY, Le Puy-en-Velay, France

🇫🇷

CHU de GRENOBLE, Grenoble, France

and more 6 locations
© Copyright 2025. All Rights Reserved by MedPath